the disease in a rural Japanese population. We have performed the survey in Matsudai town Niigara city, Japan since 1979 and the survey was performed every 7 years. In this survey, checkup included an interview, physical examination, anteroposterior standing radiographs of both knees. In this survey, knee OA was defined as being present in a knee if radiographic grade of 2 or higher with Kellegren and Lawrence (KL) scale were detected. In current study, subjects were female ages were between 60 and 80 years who attended the both 4th (2000) and 5th (2007) project of the Matsudai knee OA survey. In 5th survey, we measured urinary N-terminal crosslinking telopeptide of type I collagen (NTx) and Cterminal crosslinking telopeptide of collagen type II (CTX-II) of 564 female aged 60 and older. Occurrence of knee OA was defined if a grade 0 or 1 at the 4th survey advanced to grade 2 or higher at 5th servay. Progression of the disease was defined if a grade 2 at the fourth survey advanced to grade 3 or higher at 5th survey. We compared the data of NTx and CTX-II between occurrence and non-occurrence groups as well as between progression and non-progression groups in age ranged 60-70 year-old and 71-80 year-old. Statistical significance of a difference between two continuous variables tested by Mann-Whitney U test and a p-value of less than 0.05 was considered statistically significant. Results: In younger participants, ages between 60 to 70 years, showed the mean value of CTX-II in non-occurrence and occurrence group were 231±212 (ng/mmolCr) and 315±255 (ng/mmolCr), respectively. The mean value of CTX-II in nonprogressive OA and progressive OA were 276±246 (ng/mmolCr) and 416±314 (ng/mmolCr). We found occurrence and progression group showed significantly higher value of CTX-II in comparison non-incident or non-progression groups (47% and 50% increase, respectively) in aged between 60 to 70-year-old. In younger participants, incident group and progression group were higher amount of NTX than non-occurrence and progression group, but they are not statistically significant. People older than 71, there is no statistically significant difference in the value of CTX-II as well as NTx between incident and non-incident as well as between progression and non-progression groups. Conclusions: Currently, there are no available biomarkers which predict the disease progression of knee OA. Current study suggested that CTX-II might be a candidate as an OA incident as well as progression marker especially relatively younger female (60-70 years old) in this retrospective study of Matsudai knee OA survey.
the disease in a rural Japanese population. We have performed the survey in Matsudai town Niigara city, Japan since 1979 and the survey was performed every 7 years. In this survey, checkup included an interview, physical examination, anteroposterior standing radiographs of both knees. In this survey, knee OA was defined as being present in a knee if radiographic grade of 2 or higher with Kellegren and Lawrence (KL) scale were detected. In current study, subjects were female ages were between 60 and 80 years who attended the both 4th (2000) and 5th (2007) project of the Matsudai knee OA survey. In 5th survey, we measured urinary N-terminal crosslinking telopeptide of type I collagen (NTx) and Cterminal crosslinking telopeptide of collagen type II (CTX-II) of 564 female aged 60 and older. Occurrence of knee OA was defined if a grade 0 or 1 at the 4th survey advanced to grade 2 or higher at 5th servay. Progression of the disease was defined if a grade 2 at the fourth survey advanced to grade 3 or higher at 5th survey. We compared the data of NTx and CTX-II between occurrence and non-occurrence groups as well as between progression and non-progression groups in age ranged 60-70 year-old and 71-80 year-old. Statistical significance of a difference between two continuous variables tested by Mann-Whitney U test and a p-value of less than 0.05 was considered statistically significant. Results: In younger participants, ages between 60 to 70 years, showed the mean value of CTX-II in non-occurrence and occurrence group were 231±212 (ng/mmolCr) and 315±255 (ng/mmolCr), respectively. The mean value of CTX-II in nonprogressive OA and progressive OA were 276±246 (ng/mmolCr) and 416±314 (ng/mmolCr). We found occurrence and progression group showed significantly higher value of CTX-II in comparison non-incident or non-progression groups (47% and 50% increase, respectively) in aged between 60 to 70-year-old. In younger participants, incident group and progression group were higher amount of NTX than non-occurrence and progression group, but they are not statistically significant. People older than 71, there is no statistically significant difference in the value of CTX-II as well as NTx between incident and non-incident as well as between progression and non-progression groups. Conclusions: Currently, there are no available biomarkers which predict the disease progression of knee OA. Current study suggested that CTX-II might be a candidate as an OA incident as well as progression marker especially relatively younger female (60-70 years old) in this retrospective study of Matsudai knee OA survey. Purpose: A proteomic approach was applied to discover novel osteoarthritis specific biological markers by comparing the protein profile of urines from healthy subjects (C), or patients with osteoarthritis (OA) or osteoporosis (OP). Methods: Urine samples were collected from 10 women (76±5 years) undergoing knee replacement surgery due to severe OA, four age-matched women with severe osteoporosis (OP) and five young healthy women (C) (25.6±2.6 years) without clinical signs of joint disorders. Proteins were separated by two-dimensional difference gel electrophoresis (2D-DIGE), and the proteins with significantly increased or decreased expression in the OA sample were subject to identification by tandem mass spectrometry. Results: 19 spots intensity was increased or decreased at least 1.5 times in OA compared to C urine samples (t-test: p < 0.05). Fibulin-3 (Q12805), Zn-α2 glycoprotein precursor (P25311), apop-tosis factor 2 (Q9BRQ8), beta-actin (P60709), AMBP protein precursor (P02760), GP36b glycoprotein (Q12907), polymericimmunoglobulin receptor (P01833) were found to be increased in OA while serpin B1 (P30740), serpin B3 (P29508), kininogen-1 precursor (P01042), alpha 1 anti-trypsin (P01009), serotransferrin (P02787), mannose binding lectin associated serine protease (O00187) decreased in OA patients compared to C. Particularly, five spots containing fibulin-3 sequences were increased (by 4 to 8 fold according the isoform) in urine of patients with OA compared with those of C, but decreased (by 4 to 12 fold according the isoform) in OP urine compared with OA. Conclusions: Some of the proteins identified are known to be implicated in the inflammatory process, for example, the kininogen precursor or alpha-1-antitrypsin. This observation coincides with the pathology of osteoarthritis. A significant increase in the concentration of specific fibulin-3 fragments was observed in OA subjects compared to C and OP subjects. Functional classification indicates that fibulin-3 is related with skeletal development and its regulation by the interaction with some inhibitors of metalloproteases. These data suggest that fibulin-3 fragments could be useful biomarkers of OA.
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CARTILAGE-BONE CONTRAST BEHAVIOR IN OAI PROGRESSION SUB-COHORT; CORRELATION TO WOMAC SCORES
S.M. Totterman 1 , J. Tamez-Pena 2 , E. Schreyer 1 , P. Gonzalez 3 , D.J. Hunter 4 1 4Qimaging LLC, Rochester, NY; 2 Inst. Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Mexico; 3 IMITEK, Monterrey, Mexico; 4 Div. of Res., New England Babtist Hosp., Boston, MA Purpose: The temporal relationship between OA changes in different structures and the clinical symptoms are not understood. Image biomarkers that indicate preclinical disease or predict its symptomatic stage would have significant impact on the development of disease prevention. We investigated feasibility of a fullyautomated quantitative analysis method and used the CiPAS© software (José G Tamez-Peña, Monterrey, México) to segment and analyze bones, cartilage and anatomic regions from knee MR image data. Previous work showed that this method is repeatable and highly reproducible for regions' and structures' signal intensity measurements. In this study we compared the signal contrast at the bone-cartilage interface in the central regions of the medial and lateral compartments and the trochlea in the baseline and 1 year scans to the K&L OA grade and total WOMAC scores. Methods: The 150 subjects were from OAI Progression subcohort public use datasets 0.B.1 and 1.B.1. Their target knees' sagittal 3D DESS WE sequence (baseline, 1YR) and total WOMAC scores and K&L grades were used. The images were segmented using an automated, atlas-based method into bones, cartilage and anatomic regions. Signal intensities for the deep layer of cartilage and the superficial layer of bone were used to calculate the contrast at the bone-cartilage interface for medial and lateral tibial and femoral weight bearing regions. The contrast measurements were compared to the OA grade and total WOMAC score. We used regressions models to study the association of the contrast measurements to the WOMAC and KL scores. Image pairs that did not pass the QC were excluded from the analysis. Results: Cartilage-bone signal contrast at the central femur regions were associated to the KL scores (cMF: r=0.40, p<0.001; cLF: r=0.24, p=0.002). At baseline, the signal contrast correlated weakly with WOMAC scores in the medial weight bearing area of femur (cMF: r=0.21, β p=0.007). Figure 1 shows the box plots at three OA grades of the contrast at the cMF and the cLF (medial, lateral weight bearing region of femur). Figure 2 right, shows the
